Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2018
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 17, 2017
CompletedFirst Posted
Study publicly available on registry
November 9, 2017
CompletedStudy Start
First participant enrolled
January 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedNovember 9, 2017
November 1, 2017
6 months
June 17, 2017
November 7, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
serum LDH level as a predictor of response in hepatocellular carcinoma
To evaluate if serum LDH level can be used as a predictor of response in patients receiving different lines of treatment for hepatocellular carcinoma
2 months
Study Arms (4)
Group A
Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
Group B
Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
Group C
Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
Group D
Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
Interventions
Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
Eligibility Criteria
Patients resident at oncology department at luxor international hospital who diagnosed as apatient with Hepatocellular carcinoma
You may qualify if:
- patients with Hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein.
- signed informed consent before registration in study
- Eastern Cooperative oncology Groups Performance status between 0 and 2.
You may not qualify if:
- Cachexia or poor condition
- pregnant or human chorionic gonadotropin positive
- patient with another liver tumor
- Any previous treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Aml R Ibrahim, Lecturer
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 17, 2017
First Posted
November 9, 2017
Study Start
January 2, 2018
Primary Completion
July 1, 2018
Study Completion
December 1, 2018
Last Updated
November 9, 2017
Record last verified: 2017-11